Company intelligence / Profile preview

Imexpharm

Ownership: Private
Employees: ~1446
Development stage: Commercial

Overview

Imexpharm has established itself as Vietnam’s leading pharmaceutical manufacturer with the most EU-GMP certified production lines in the country. The company operates four factory clusters—three of which meet EU-GMP standards—and by July 2024 had secured European market authorizations for eleven products. It serves both domestic and international markets with a broad portfolio of high-quality generic pharmaceuticals across multiple therapeutic areas.

Therapeutic areas: PulmonologyEndocrinologyImmunologyRheumatologyGastroenterologyCardiovascularOphthalmologyNeurologyInfectious Diseases
Modalities: Small molecules (oral and injectable antibiotics)Traditional medicinesVitamins & minerals supplementsExternal drugs (topicals)Medical devices and supplies
Industry: Biotech

Partnerships

Sandoz (Novartis)Pharmacience CanadaSanofi-Aventis

Beyond the preview

Go deeper on Imexpharm.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Imexpharm.

Explore the full profile